Relmada Therapeutics (RLMD) Proxy filing summary

Executive summary

• 2025 was a transformational year, marked by a strategic pivot after a failed lead program, disciplined expense management, and successful acquisition of two clinical-stage assets, NDV-01 and sepranolone, positioning the company for renewed value creation and a robust clinical pipeline.

• Share price rebounded from $0.24 to $4.83, market cap rose from $7M to $353M, and cash position improved to $100M after a successful $100M financing round with strategic investor participation.

• The company retained and enhanced its core team, notably adding a Chief Medical Officer for Urology, and maintained NASDAQ listing through proactive investor engagement.

Voting matters and shareholder proposals

• Shareholders will vote on electing two Class II directors for three-year terms, ratifying CBIZ CPAs P.C. as independent auditor, amending the 2021 Equity Incentive Plan to add 3M shares, and increasing authorized common stock from 150M to 200M shares.

• The board recommends voting “FOR” all proposals.

Board of directors and corporate governance

• The board consists of five members, with a majority deemed independent under Nasdaq rules; leadership roles of Chairman and CEO are separated.

• Three standing committees: audit, compensation, and nominating/corporate governance, each with independent directors and reviewed charters.

• Diversity in experience, skills, and background is considered in director nominations.

• Seven board meetings were held in 2025, with full attendance.